Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico

  • Cynthia M Pérez1Email author,
  • Edmir Marrero1,
  • Marytere Meléndez1,
  • Sandra Adrovet1,
  • Héctor Colón2,
  • Ana P Ortiz1, 3,
  • Marievelisse Soto-Salgado1, 4,
  • Carmen Albizu2,
  • Esther A Torres5 and
  • Erick Suárez1
BMC Infectious Diseases201010:76

DOI: 10.1186/1471-2334-10-76

Received: 6 November 2009

Accepted: 23 March 2010

Published: 23 March 2010

Abstract

Background

Viral hepatitis and sexually transmitted infections (STIs) are key public health problems that pose an enormous risk for disease transmission in the general population. This study estimated, for the first time, prevalence estimates of serologic markers of HCV, HBV, HAV, HIV and HSV-2 in the adult population of Puerto Rico and assessed variations across sociodemographic and behavioral characteristics.

Methods

A seroepidemiologic survey was employed using a stratified cluster probability sample of households in Puerto Rico. Participants completed a face-to-face interview, a self-administered questionnaire using an ACASI system, and provided blood specimens for antibody testing. Prevalence estimates of viral hepatitis, HIV and HSV-2 were estimated using a logistic regression model weighting for the probability of participation in each household block and the inverse of the probability of selection according to geographic strata, households' blocks, and sex distribution.

Results

A total of 1,654 adults participated in the study. Seroprevalence estimates for HCV (2.3%, 95% CI: 1.3%-4.2%), HBV (3.1%, 95% CI: 2.0%-4.7%), and HSV-2 (22.3%, 95% CI: 18.5%-26.7%) in Puerto Rico are roughly in agreement with estimates obtained in the US population; however, HAV (41.3%, 95% CI: 36.9%-45.8%) and HIV (1.1%, 95% CI: 0.5%-2.3%) seroprevalence estimates in Puerto Rico were higher. The proportion of individuals that were unaware of their serostatus was as follows: 80% for HCV, 98.3% for HBV, 96.4% for HAV, 36.4% for HIV, and 97.8% for HSV-2. Post-stratification estimates of seroprevalence varied significantly by demographic and risk related characteristics.

Conclusion

This data underscore the disproportionate impact of some viral infections across selected population subgroups in Puerto Rico. A concerted island-wide effort is needed to strengthen viral hepatitis and STIs prevention and control strategies, support surveillance to monitor chronic infections, and ensure appropriate counseling, testing, and medical management of infected persons. Integration of HCV, HBV, and HSV-2 counseling into HIV existing prevention services and outreach through social networks might represent a valuable approach to reach high-risk individuals.

Background

Viral hepatitis and sexually transmitted infections (STIs) are key public health threats that pose an enormous risk for disease transmission in the general population. Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are a leading cause of hepatocellular carcinoma, a condition whose incidence rate remains high in the developing world and is rising across most developed countries [1]. In 2007, the Centers for Disease Control and Prevention estimated that 85,000 new acute viral hepatitis cases and nearly 19 million new STIs occurred in the United States (US) [2, 3]. In addition to the physical and psychological consequences of these diseases, the economic impact of STIs and of the viral hepatitis in the US are conservatively estimated at $15.3 billion annually, based on 2007 dollars, and $1.8 billion, based on 1999 dollars, respectively [4, 5]. Taking into account that these statistics do not reflect the true burden of viral hepatitis caused by chronic infection with HBV and HCV, that many cases of notifiable acute hepatitis and STIs are undiagnosed, and some common viral infections, such as genital herpes and human papillomavirus infection, are not notifiable infectious diseases in the US, the true burden of viral hepatitis and STIs is underestimated [2, 3, 5, 6].

Viral hepatitis and STIs share similar at-risk populations and risk factors. For example, those who are infected with certain STIs have a three to five-fold increased risk for HIV infection, 33% of all HIV-infected persons are HCV infected, and 5-15% of HIV-infected persons are co-infected with HBV [7, 8]. These diseases also share similar social determinants, including poor access to health care, stigma, discrimination, homophobia, and poverty [5, 6].

The National Health and Nutrition Examination Survey (NHANES) has provided reliable estimates of viral hepatitis (HCV, HBV, and hepatitis A virus (HAV)) and STIs including HIV and herpes simplex virus type 2 (HSV-2) across various racial and ethnic groups in the US [914]. However, Puerto Rico, as a jurisdiction, is excluded from NHANES. Accurate estimates for the impact of these viral infections in this Hispanic subgroup are important for predicting future trends and directing preventive efforts. Although the HIV/AIDS epidemic has disproportionately affected Puerto Ricans, with estimated rates per 100,000 population of 223.0 for HIV and 354.7 for AIDS during 2007, population-based surveys on viral hepatitis and STIs in Puerto Rico are scant [1517]. Information on the burden of HIV and other STIs in Puerto Rico has relied upon surveillance systems or respondents' self-reports of symptoms and diagnoses provided in the Behavioral Risk Factor Surveillance Survey (BRFSS). Meanwhile, epidemiologic data regarding the burden of viral hepatitis and related complications are limited in scope and comprehensiveness [17], limiting the planning of prevention interventions and monitoring their effectiveness to control these infections. We determined for the first time prevalence estimates of serologic markers of HCV, HBV, HAV, HIV and HSV-2 and assessed variations across sociodemographic and behavioral characteristics in the adult population of Puerto Rico.

Methods

Study Design and Sampling Procedures

Detailed descriptions of the survey design and recruitment have been published elsewhere [18, 19]. Briefly, a seroepidemiologic survey was designed using a stratified, multistage, probability cluster sample of all households in Puerto Rico. To define the sampling frame, Puerto Rico was stratified on the basis of AIDS incidence rates among injecting drug users (IDUs) and adult population density. The configuration of the sample strata assumed that HCV seroprevalence would vary systematically across the four strata and that prevalence estimates would gain precision. Four strata were derived corresponding to municipalities with above and at or below median AIDS incidence rates among IDUs (9.9/100,000 population reported in Puerto Rico in 2002) and above and at or below median population density (486 per square mile). Statistics provided by the Puerto Rico AIDS Surveillance System [20] were used to determine the incidence rate of AIDS among IDUs in each municipality in Puerto Rico during 2002. An estimated sample size of 2,000 adults randomly selected among strata of equal sizes was calculated on the basis of an expected prevalence of HCV infection of 6.3%, 95% confidence level and precision level of 3% [17, 21]. Due to the complex sampling design, the prevalence estimation was weighted according to the inverse of probability of selection and participation rate in each selected block. The probability of selection was defined as a function of the geographic strata, households' blocks, and sex distribution according to post-censal estimates in Puerto Rico.

Household individuals within each stratum were selected in four stages. In the first stage, census blocks were sorted by median age and median housing value to achieve adequate representation of disease burden across all age groups and socioeconomic levels, and a systematic random selection was made with probability proportional to the number of households. The second selection stage consisted of a random selection of one block within each census block group. In a third stage, one segment of approximately 25 consecutive households was randomly selected from each block. A total of 108 segments were selected comprising 3,487 occupied households. Enumerators were able to contact residents in 3,386 households (97.1%), and 2,123 of these households had at least one adult aged 21 to 64 years old. In the final stage, one eligible adult was randomly selected from each household and invited to participate in the study.

Participants were given an appointment to visit a mobile examination unit located in the vicinity of their homes. At the mobile examination unit, a formal informed consent procedure was conducted which provided participants with information of all study procedures. Upon formally consenting, participants were offered pretest counseling. Participants completed a face-to-face interview and then were asked to complete a self-administered questionnaire using an ACASI system implemented using QDS (Nova Research Co., Washington, D.C.). After interviewing, a certified phlebotomist collected blood specimens of 15-ml for HAV, HBV, HCV, HIV, and HSV-2 testing. Participants received a $50.00 financial compensation upon completion of the study procedures for their time effort in addition to educational materials on prevention of blood-borne infections, STIs and enteric infections. Participants, whose test results were positive, received post-counseling and referrals for follow-up medical evaluation. Field work was conducted between June 2005 and February 2008. All human subjects provided informed consent for this study under a protocol (number #A0420105) approved by the University of Puerto Rico Medical Sciences Campus institutional review board.

Measures

Face-to-face interviews covered standard sociodemographic characteristics plus extensive information on medical diagnoses including other STIs (self-reported syphilis, gonorrhea, genital warts, and infection with genital Chlamydia trachomatis), tattooing and body piercing practices, knowledge on viral infections under study, and self-reports of HAV and HBV vaccination coverage. The ACASI system ascertained cigarette and alcohol use, lifetime and recent drug use, sex-related risk behaviors, and history of incarceration. Trained interviewers conducted the personal interview and were available to answer questions during the self-administered interview.

Laboratory Analyses

Testing for antibody to HCV was performed with a chemiluminiscent immunoassay (ADVIA Centaur®, Siemens Healthcare Diagnostics, Deerfield, IL) and confirmation by recombinant immunoblot assay (Laboratory Corporation of America® Holdings, Tampa, FL). HBV antibodies were assayed with a chemiluminiscent immunoassay (IMMULITE® 2000, Siemens Healthcare Diagnostics, Los Angeles, CA) for total hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs). HBV serologic testing results were classified as follows: past or present infection (HbsAg negative, anti-HBc positive and anti-HBs positive; HBsAg positive, anti-HBc positive and anti-HBs negative) and serologic evidence of vaccination (anti-HBs positive, HBsAg negative and anti-HBc negative). Total HAV antibodies were measured by a chemiluminiscent immunoassay (ADVIA Centaur®, Siemens Healthcare Diagnostics, Deerfield, IL). HIV-1 antibodies were assayed with commercial enzyme immunoassay (Evolis™ Bio-Rad Laboratories, Inc., Hercules, CA) and confirmed by Western blot (Laboratory Corporation of America® Holdings, Tampa, FL). HSV-2 type-specific IgG was tested via enzyme immunoassay (Laboratory Corporation of America® Holdings, Tampa, FL).

Statistical Analysis

Prevalence estimates of viral hepatitis (HAV, HBV, HCV), HIV and HSV-2 were estimated using logistic regression models weighting for the probability of participation in each household block and the inverse of the probability of selection according to the geographic strata, households' blocks, and sex distribution in Puerto Rico. To account for the correlation between subjects selected from the same block segment, the parameters of this model were estimated using a generalized estimating equations approach [22]. Population estimates were generated by multiplying population counts obtained from the postcensal estimates of the civilian, noninstitutionalized population aged 21-64 years as of July 1, 2008 by the weighted prevalence estimate and rounded to the nearest thousand [23]. Data management and statistical analyses were performed using the statistical package Stata (Version 10.0, College Station, TX, USA).

Results

Characteristics of Study Population

Of the selected residents, 1,654 (77.9%) consented to participate in the face-to-face interview and provided blood samples suitable for antibody testing for viral infections. The age distribution of study participants (21-29 years: 22.2%; 30-39 years: 24.2%; 40-49 years: 26.3%; 50-64 years: 27.3%) was similar to that of the adult population of Puerto Rico according to the Census 2000 [24] (Table 1). Females were slightly overrepresented in that they made up 56.4% of the study sample. Nearly 75% reported to have completed high school, 66.2% were living below the poverty level (annual family income below $20,000), and 10.5% did not have health care coverage at the time of the interview. More than half (51.3%) reported first sexual intercourse before age 18, 58% reported 2-9 lifetime sexual partners, and 6.1% of men had a history of sexual contact with same-sex partners. Over one-third (35.5%) of participants reported lifetime non-injection drug use, whereas 1.5% reported injection drug use. Marijuana (29.3%), cocaine (14.9%), and heroin (6.5%) were the most commonly used drugs. Nearly 15% informed tattooing practices, 30.1% had a history of ear or other body piercing, 4.8% reported receipt of blood transfusions prior to 1992, 5.2% had a history of other STIs, and 8.2% had a history of imprisonment. Self-reported vaccination coverage for HAV, defined as having received two doses of the vaccine, was indicated by only 1.6% of participants, whereas 13.2% had serologic evidence of hepatitis B vaccination.
Table 1

Demographic and risk-related characteristics of 1,654 adults aged 21-64 in Puerto Rico, 2005-2008

Characteristics

Numbera

Percent (%)

Age in years

  

   21-29

367

22.2

   30-39

400

24.2

   40-49

435

26.3

   50-64

452

27.3

Sex

  

   Female

933

56.4

   Male

721

43.6

Years of education

  

   ≥ 12

1237

74.8

   < 12

417

25.2

Annual family income

  

   ≥ 20,000

515

33.8

   < $20,000

1011

66.2

Health care coverage

  

   Private

746

45.1

   Public

735

44.4

   None

173

10.5

Age in years at first sexual intercourse

  

   < 12

42

2.6

   12-17

762

48.7

   ≥ 18

762

48.7

Number of lifetime sexual partners

  

   0-1

336

21.9

   2-9

890

58.0

   ≥ 10

308

20.1

Men who have sex with men

  

   Never

633

93.9

   Ever

41

6.1

Lifetime drug use

  

   None

1042

63.0

   Non-IDU

587

35.5

   IDU

25

1.5

Type of substance useb

  

   Marijuana

484

29.3

   Cocaine

246

14.9

   Heroin

108

6.5

Tattooing practice

  

   Never

1409

85.2

   Ever

244

14.8

Body piercing

  

   Never

1154

69.9

   Ever

498

30.1

Blood transfusions prior to 1992

  

   Never

1574

95.2

   Ever

80

4.8

History of other STIsc

  

   No

1568

94.8

   Yes

86

5.2

History of imprisonment

  

   Never

1518

91.8

   Ever

136

8.2

Self-reported HAV vaccination coverage

  

   No

1628

98.4

   Yes

26

1.6

Serologic evidence of HBV vaccination

  

   No

1435

86.8

   Yes

219

13.2

aTotal may not equal the overall sample size because of non-response.

bCategories of substance use are not mutually exclusive.

cSelf-reported history of syphilis, gonorrhea, genital warts, and chlamydia infection.

Prevalence estimation

HCV

Weighted prevalence was 2.3% (95% CI: 1.3% - 4.2%), corresponding to 53,000 (95% CI: 30,000 - 95,000) HCV antibody-positive persons in Puerto Rico (Table 2). This prevalence increased to 2.7% in strata 3 and 4, municipalities with a high incidence of AIDS among injecting drug users. Most of these individuals (80%) were unaware of their HCV serostatus (data not shown). Although the peak in age-specific prevalence was observed among people aged 40-49 years (2.7%) and was lowest among those aged 50-64 years (1.3%), variations across age groups were not statistically significant (Table 3). Anti-HCV prevalence was significantly higher in men (4.0%) and those with public (4.1%) or no health insurance (2.9%) (p < 0.01 and p < 0.001, respectively). Prevalence did not vary according to education and annual family income. When high risk behaviors were examined, anti-HCV prevalence was significantly (p < 0.001) higher for those who had first sex before the age of 12 years (10.2%) and among persons reporting at least 10 lifetime sexual partners (5.5%) but not among men who had sex with men. Anti-HCV prevalence was significantly (p < 0.001) higher among persons who had ever injected drugs (76.1%) compared to those who had ever used non-injection drugs (1.8%) or those who had never used drugs (0.6%). Anti-HCV was also significantly (p < 0.05) correlated with a history of tattooing practice (10.2%), body piercing (4.0%), receipt of blood transfusions before 1992 (6.3%), history of imprisonment (17.5%) but not with a history of other STIs. Positivity to HBV (17.4%) and HSV-2 (5.1%) antibody testing were significantly (p < 0.01) associated to HCV seropositivity (Table 4).
Table 2

Weighted seroprevalence (%) of selected viral infections among adults 21-64 years: Puerto Rico, 2005-2008

 

Weighted prevalence of antibodies

Estimated number of adults infected in Puerto Ricoa

 

Prevalence

95% CI

Number

95% CI

HCV (n = 1,650)

2.3

1.3 - 4.2

53000

30000 - 95000

   Stratum 1b

2.1

1.1 - 4.1

9000

5000 - 17000

   Stratum 2c

0.5

0.1 - 2.1

3000

1000 - 10000

   Stratum 3d

2.7

1.6 - 4.8

8000

5000 - 13000

   Stratum 4e

2.7

1.5 - 4.7

30000

17000 - 52000

HBV (n = 1,654)

3.1

2.0 - 4.7

71000

47000 - 108000

   Stratum 1b

5.3

3.6 - 7.8

23000

15000 - 33000

   Stratum 2c

2.6

1.4 - 4.6

12000

7000 - 22000

   Stratum 3d

2.8

1.5 - 5.1

8000

5000 - 14000

   Stratum 4e

2.9

1.7 - 5.0

33000

19000 - 56000

HAV (n = 1,650)

41.3

36.9 - 45.8

933000

834000 - 1035000

   Stratum 1b

42.5

37.9 - 47.3

178000

159000 - 198000

   Stratum 2c

38.5

33.9 - 43.3

180000

158000 - 202000

   Stratum 3d

42.4

37.6 - 47.4

113000

100000 - 126000

   Stratum 4e

42.0

37.2 - 46.8

465000

413000 - 520000

HIV (n = 1,650)

1.1

0.5 - 2.3

25000

12000 - 51000

   Stratum 1b

0.2

0.03 - 1.4

1000

1000 - 6000

   Stratum 2c

0.2

0.03 - 1.6

2000

1000 - 8000

   Stratum 3d

0.7

0.2 - 2.1

2000

1000 - 6000

   Stratum 4e

1.3

0.6 - 3.0

15000

7000 - 34000

HSV-2 (n = 1,446)

22.3

18.5 - 26.7

505000

418000 - 603000

   Stratum 1b

19.7

16.0 - 24.1

83000

67000 - 101000

   Stratum 2c

22.0

18.1 - 26.5

103000

85000 - 124000

   Stratum 3d

24.9

20.5 - 29.8

66000

55000 - 80000

   Stratum 4e

22.1

18.1 - 26.7

246000

201000 - 297000

aEstimated numbers and their associated 95% CI are rounded to the nearest thousand.

bStrata 1 include municipalities with low AIDS incidence rates among IDUs and low population density. cStrata 2 include municipalities with low AIDS incidence rates among IDUs and high population density. dStrata 3 include municipalities with high AIDS incidence rates among IDUs and low population density. eStrata 4 include municipalities with high AIDS incidence rates among IDUs and high population density.

Table 3

Weighted seroprevalence of viral infections by selected sociodemographic characteristics and risk behaviors: Puerto Rico, 2005-2008.

Characteristics

Prevalence (%) (95% CI)

 

Anti-HCV

Anti-HBV

Anti-HAV

Anti-HIV

Anti-HSV-2

Age in years

     

   21-29

2.3 (0.8 - 6.6)

1.2 (0.4 - 3.3)a

8.2 (5.1 - 12.7)c

*b, d

14.8 (10.5 - 20.3)c

   30-39

2.5 (1.2 - 4.9)

2.7 (1.3 - 5.4)

13.9 (9.9 - 19.2)

1.0 (0.3 - 3.5)

15.5 (10.7 - 21.8)

   40-49

2.7 (1.3 - 5.4)

3.6 (2.1 - 6.2)

49.4 (41.7 - 57.2)

1.7 (0.6 - 4.7)

29.1 (24.2 - 34.5)

   50-64

1.3 (0.4 - 4.4)

5.4 (3.3 - 8.6)

89.0 (84.6 - 92.2)

0.7 (0.2 - 2.0)

29.0 (23.3 - 35.4)

Sex

     

   Female

1.0 (0.4 - 2.1)b

2.5 (1.6 - 3.9)

41.3 (36.7 - 46.0)

0.8 (0.3 - 2.0)

25.6 (21.5 - 30.2)b

   Male

4.0 (2.3 - 6.8)

4.3 (2.7 - 6.8)

41.5 (36.7 - 46.5)

1.0 (0.4 - 2.4)

17.8 (14.3 - 22.1)

Years of education

     

   ≥ 12

2.2 (1.3 - 3.6)

2.5 (1.7 - 3.9)a

35.8 (32.3 - 39.4)c

0.6 (0.2 - 1.5)

20.2 (17.2 - 23.5)b

   < 12

2.3 (1.0 - 5.3)

5.7 (3.7 - 8.6)

59.3 (54.5 - 63.9)

1.7 (0.7 - 4.3)

29.3 (22.8 - 36.8)

Annual family income

     

   ≥ $20,000

1.4 (0.4 - 4.4)

1.1 (0.5 - 2.6)b

32.9 (28.6 - 37.5)c

1.1 (0.4 - 3.4)

16.9 (12.8 - 21.9)b

   < $20,000

2.3 (1.3 - 4.0)

4.0 (2.9 - 5.6)

45.9 (41.8 - 50.1)

0.6 (0.2 - 1.6)

25.9 (21.8 - 30.5)

Health care coverage

     

   Private

0.4 (0.2 - 0.9)c

2.2 (1.3 - 3.7)

43.8 (38.9 - 48.9)

0.8 (0.2 - 2.3)

17.3 (14.0 - 21.3)c

   Public

4.1 (2.4 - 6.9)

4.5 (3.0 - 6.7)

40.6 (36.0 - 45.3)

0.8 (0.3 - 1.9)

27.6 (23.0 - 32.6)

   None

2.9 (0.8 - 9.6)

3.4 (1.4 - 8.2)

33.9 (24.2 - 45.1)

1.6 (0.3 - 7.8)

24.0 (16.5 - 33.6)

Age at first sexual intercourse

     

   < 12

10.2 (3.3 - 27.2)c

15.2 (5.7 - 34.5)b

57.2 (38.8 - 73.8)

2.0 (0.5 - 8.4)

33.1 (18.7 - 51.6)

   12-17

3.6 (2.0 - 6.1)

3.7 (2.4 - 5.7)

38.3 (33.9 - 42.9)

0.9 (0.4 - 2.3)

23.9 (19.4 - 29.2)

   ≥ 18

0.5 (0.2 - 1.1)

1.9 (1.1 - 3.3)

43.2 (38.9 - 47.6)

0.3 (0.1 - 1.6)

20.1 (16.4 - 24.4)

Number of lifetime sexual partners

     

   0-1

0.7 (0.1 - 3.3)c

1.9 (0.9 - 4.0)

50.9 (44.3 - 57.6)b

*d

11.5 (7.9 - 16.5)c

   2-9

1.2 (0.6 - 2.6)

2.7 (1.8 - 4.2)

37.4 (33.5 - 41.4)

0.9 (0.4 - 2.3)

24.1 (20.1 - 28.6)

   ≥ 10

5.5 (3.0 - 9.8)

4.6 (2.6 - 8.0)

41.5 (33.2 - 50.3)

0.7 (0.2 - 1.9)

25.1 (19.9 - 31.1)

Men who have sex with men

     

   Never

4.0 (2.3 - 6.9)

4.3 (2.6 - 7.1)

41.2 (36.3 - 46.2)

0.3 (0.1 - 0.9)c

16.8 (12.9 - 21.5)

   Ever

2.6 (0.7 - 9.3)

3.1 (0.7 - 13.0)

49.9 (31.9 - 67.9)

7.3 (1.9 - 24.5)

22.0 (11.5 - 38.1)

Lifetime drug use

     

   None

0.6 (0.2 - 1.6)c

2.6 (1.7 - 3.9)c

47.7 (44.1 - 51.4)c

0.7 (0.3 - 1.9)

20.3 (16.6 - 24.5)

   Non-IDU

1.8 (0.9 - 3.5)

3.5 (2.1 - 5.8)

29.3 (24.3 - 34.9)

1.0 (0.4 - 2.8)

25.4 (20.9 - 30.6)

   IDU

76.1 (55.2 - 89.1)

23.5 (8.8 - 49.3)

66.9 (42.9 - 84.5)

2.8 (0.6 - 12.4)

31.9 (10.3 - 65.5)

Tattooing practice

     

   Never

0.9 (0.5 - 1.6)c

2.9 (2.0 - 4.0)

43.7 (40.4 - 47.0)c

0.6 (0.3 - 1.4)

21.8 (18.2 - 25.8)

   Ever

10.2 (6.0 - 16.8)

5.6 (2.8 - 11.1)

27.5 (21.4 - 34.6)

2.2 (0.6 - 7.1)

26.2 (19.8 - 33.9)

Body piercing

     

   Never

1.4 (0.8 - 2.6)a

3.6 (2.5 - 5.1)

48.9 (45.2 - 52.7)c

1.0 (0.5 - 2.2)

23.0 (20.0 - 26.4)

   Ever

4.0 (2.1 - 7.5)

2.7 (1.3 - 5.6)

24.4 (19.9 - 29.6)

0.5 (0.1 - 2.1)

21.0 (15.8 - 27.5)

Blood transfusions prior to 1992

     

   Never

2.0 (1.2 - 3.2)b

2.9 (2.1 - 4.0)b

40.1 (37.1 - 43.3)c

0.4 (0.2 - 1.0)c

21.9 (18.6 - 25.6)

   Ever

6.3 (2.5 - 14.6)

11.6 (5.3 - 23.6)

65.2 (52.7 - 75.8)

9.2 (3.4 - 22.8)

31.2 (19.6 - 45.7)

History of other STIse

     

   Yes

2.7 (0.7 - 9.1)

4.9 (2.2 - 10.7)

47.3 (35.0 - 59.8)

5.9 (1.9 - 16.5)b

33.9 (22.7 - 47.3)a

   No

2.2 (1.3 - 3.6)

3.2 (2.3 - 4.5)

41.1 (37.9 - 44.3)

0.6 (0.3 - 1.4)

21.9 (18.6 - 25.6)

History of imprisonment

     

   Never

0.8 (0.4 - 1.5)c

2.6 (1.8 - 3.7)b

41.2 (37.8 - 44.7)

0.6 (0.2 - 1.3)b

21.1 (18.1 - 24.5)b

   Ever

17.5 (11.4 - 26.1)

11.2 (5.4 - 21.7)

43.0 (33.5 - 53.0)

4.1 (1.4 - 10.9)

36.0 (25.4 - 48.0)

aP < 0.05; bP < 0.01; cP < 0.001.

dIndicates a relative standard error of 30% or more, thus this reflects a potentially unreliable estimate and is not shown.

eSelf-reported history of syphilis, gonorrhea, genital warts, and chlamydia infection.

Table 4

Prevalence of concomitant antibodies to viral hepatitis, HIV and HSV-2, Puerto Rico, 2005-2008.

 

Prevalence (%) (95% CI)

Characteristic

Anti-HCV

Anti-HBV

Anti-HAV

Anti-HIV

Anti-HSV-2

Antibody to HCV

     

   Positive

--

27.1 (13.9 - 46.0)a

61.2 (34.5 - 82.5)

2.2 (0.5 - 8.6)

55.4 (30.9 - 77.6)b

   Negative

--

2.7 (2.0 - 3.8)

40.9 (37.8 - 44.1)

0.8 (0.4 - 1.6)

21.7 (18.5 - 25.3)

Antibody to HBV

     

   Positive

17.4 (8.5 - 32.3)a

--

71.5 (56.7 - 82.7)a

--

39.9 (27.5 - 53.7)b

   Negative

1.7 (1.0 - 2.8)

--

40.3 (37.1 - 43.6)

--

21.7 (18.6 - 25.3)

Antibody to HAV

     

   Positive

3.3 (1.8 - 6.1)

5.7 (3.9 - 8.3)a

--

1.4 (0.6 - 3.0)

29.4 (24.8 - 34.5)a

   Negative

1.4 (0.6 - 3.2)

1.6 (1.0 - 2.7)

--

0.5 (0.1 - 1.7)

17.6 (14.2 - 21.5)

Antibody to HIV

     

   Positive

5.2 (1.0 - 23.0)

--

66.2 (29.5 - 90.1)

--

89.3 (57.0 - 98.1)a

   Negative

2.2 (1.3 - 3.5)

--

41.1 (37.9 - 44.4)

--

21.9 (18.7 - 25.4)

Antibody to HSV-2

     

   Positive

5.1 (2.5 - 10.1)b

6.2 (3.9 - 9.8)b

53.7 (46.5 - 60.8)a

3.0 (1.2 - 6.9)a

--

   Negative

1.2 (0.6 - 2.3)

2.7 (1.8 - 3.9)

36.9 (33.9 - 40.0)

0.1 (0.02 - 0.4)

--

--, Not applicable.

aP < 0.001; bP < 0.01.

HBV

Weighted prevalence of past or present infection with HBV was 3.1% (95% CI: 2.0% - 4.7%), equating to 71,000 (95% CI: 47,000 - 108,000) adults with past or present HBV infection in Puerto Rico (Table 2). Prevalence of past or present infection with HBV was similar across strata. The majority of HBV seropositive individuals (98.3%) were unaware of their serostatus (data not shown). Prevalence of past or present HBV infection increased significantly (p < 0.05) with age, reaching 5.4% among individuals aged 50-64 years (Table 3). Although prevalence was higher in males (4.3%) and among those with public (4.5%) or no health insurance (3.4%), the differences were marginally significant (p = 0.07 and p = 0.097, respectively). Prevalence was significantly (p < 0.05) higher in those with less than 12 years of education (5.7%), those living below the poverty level (4.0%), those who had first sex before the age of 12 years (15.2%), persons who had ever injected drugs (23.5%), and those with a history of receiving blood transfusions before 1992 (11.6%) and imprisonment (11.2%). People with positive antibody testing results for HCV (27.1%), HAV (5.7%) and HSV-2 (6.2%) had significantly (p < 0.01) higher HBV seroprevalence than those with negative results (Table 4).

HAV

Weighted prevalence of anti-HAV was 41.3% (95% CI: 36.9% - 45.8%), and the estimated number of adults ever infected with HAV in Puerto Rico was 933,000 (95% CI: 834,000 - 1,035,000) (Table 2). No marked variations in HAV seroprevalence were observed across strata. Most of HAV seropositive individuals (96.4%) were unaware of their serostatus (data not shown). Prevalence of anti-HAV increased steeply (p < 0.001) with age, from 8.2% in persons aged 21-29 years to 89.0% in those aged 50-64 years (Table 3). Similarly, prevalence was significantly (p < 0.001) higher in people who had less than 12 years of education (59.3%) and lower annual family income (45.9%). Moreover, anti-HAV prevalence was higher (p < 0.01) among those who reported either one or no sexual partner (50.9%), injection drug use (66.9%), no history of tattooing or body piercing practices (43.7% and 48.9%, respectively), and receipt of blood transfusions prior to 1992 (65.2%). Individuals with positive results on HBV (71.5%) and HSV-2 (53.7%) antibody testing had significantly (p < 0.001) higher seroprevalence of HAV than seronegative individuals (Table 4).

HIV

Weighted prevalence was 1.1% (95% CI: 0.5% - 2.3%), corresponding to 25,000 (95% CI: 12,000 - 51,000) persons ever infected with HIV in the adult population of Puerto Rico (Table 2). This prevalence reached 1.3% in stratum 4 (municipalities with a high population density and high AIDS incidence rate among IDUs). The percentage of HIV seropositive individuals who were unaware of their status was 36.4% (data not shown). Prevalence of HIV was significantly (p < 0.05) higher in adults aged 40-49 years (1.7%), men who had sex with men (7.3%), those who reported receipt of blood transfusions prior to 1992 (9.2%), and individuals with a history of other STIs (5.9%) and imprisonment (4.1%) (Table 3). Adults who were seropositive to HSV-2 had a significantly higher prevalence of HIV antibodies than those who were seronegative (3.0% vs. 0.1%, p < 0.001) (Table 4).

HSV-2

Weighted prevalence was 22.3% (95% CI: 18.5% - 26.7%), equating to 505,000 (95% CI: 418,000 - 603,000) seropositive individuals to HSV-2 in the adult population of Puerto Rico (Table 2). Most of these individuals (97.8%) were unaware of their HSV-2 serostatus (data not shown). Seroprevalence was significantly (p < 0.01) higher among adults aged 40-49 and 50-64 years (29.1% and 29.0%, respectively) and females (25.6%) (Table 3). Prevalence was also significantly (p < 0.01) higher among those who had less than 12 years of education (29.3%), lived below the poverty level (25.9%), and were covered by public health insurance or were uninsured (27.6% and 24.0%, respectively). HSV-2 seropositivity significantly (p < 0.001) increased with the lifetime number of sexual partners, from 11.5% for one partner or less to 25.1% for those with at least 10 sexual partners. Individuals who reported a history of other STIs and those with a history of imprisonment were also significantly more likely to be HSV-2 seropositive than those without such histories (33.9% vs. 21.9%, p < 0.05; 36.0% vs. 21.1%, p < 0.01; respectively). People with positive results for anti-HCV (55.4%), anti-HBV (39.9%), anti-HAV (29.4%), and anti-HIV (89.3%) had significantly (p < 0.01) higher seroprevalence of HSV-2 compared to those with negative results (Table 4).

Discussion

To our knowledge, this is the first population-based survey that provides nationally representative estimates of the seroprevalence of viral hepatitis, HIV and HSV-2 in the non-institutionalized adult population of Puerto Rico, vital information that provides insight into disease burden and opportunities for prevention. Seroprevalence estimates for HCV (2.3%), HBV (3.1%), and HSV-2 (22.3%) in Puerto Rico are roughly in agreement with estimates obtained in the US population aged 20-59 years, where age-adjusted prevalence was 2.4% for HCV (1.6% in the most recent NHANES), 5.6% for HBV, and 25.1% for HSV-2 [912]. However, HIV and HAV seroprevalence estimates in Puerto Rico (1.1% and 41.3%, respectively) were higher than the corresponding figures for the US adult population (0.5% and 30.7%, respectively) [13, 14]. The higher HIV seroprevalence found in this study is consistent with national surveillance data showing that Puerto Rico has one of the highest overall rates of HIV/AIDS among states and territories of the US, mainly attributed to sharing of contaminated injecting equipment [15, 16]. The higher HAV seroprevalence might be attributed to poorer economic development, sanitation, and environmental conditions in Puerto Rico [13, 25]. However, prevalence estimates for viral hepatitis, HIV and HSV-2 in these studies are probably underestimated because the sampling frame excluded subpopulations at high risk of these infections including the homeless and incarcerated individuals [26, 27].

The vast majority of individuals first learned of their viral hepatitis and HSV-2 serostatus from this survey. These findings parallel results from other studies that have consistently found that a large percentage of the population is not aware of their serostatus due to the asymptomatic nature of these infections [11, 28]. The percentage of people unaware of their HIV seropositivity (36%), although substantially lower than for the other viral infections under study, is higher than the estimate in the US, where approximately 21% of HIV-positive persons remain undiagnosed [29]. This finding calls for a multisectoral approach to the HIV/AIDS epidemic in Puerto Rico to improve counseling, testing, and linkage to appropriate care and treatment services among high-risk individuals. In addition, widespread implementation of prevention interventions with proven efficacy could further prevent transmission of HIV [30]. Taking into consideration that the prevalence of antibodies to HCV, HBV and HSV-2 were considerably higher than the prevalence of HIV, the need for effective approaches for the prevention and control of viral hepatitis and other STIs is underscored. To increase knowledge and awareness of these infections among health care providers, at-risk populations and the public, integration of HCV, HBV and HSV-2 counseling and screening into HIV existing prevention services and outreach through social, sexual and drug-using networks might represent a valuable approach to reach high-risk individuals [31].

Dramatic variations in the prevalence of antibodies to viral hepatitis, HIV and HSV-2 were observed according to demographic and behavioral factors. As expected, anti-HAV increased markedly with age, primarily reflecting infection in the older cohorts that were acquired during childhood [13, 25]. Antibodies to both HBV and HSV-2 also increased with age, findings consistent with reports from different geographic areas [10, 12, 32]. HIV seroprevalence increased to a peak of 1.7% in those aged 40-49 years and decreased to 0.7% in those aged 50-64 years. These observations are also consistent with HIV surveillance data in Puerto Rico where the majority of new infections in 2006 occurred among persons aged 30-49 years [16].

Significant sex differences were found for seroprevalence of HCV and HSV-2. Men were four times more likely to be anti-HCV positive, a finding that is in agreement with several population-based surveys, possibly reflecting riskier drug behaviors in males [11, 33]. On the other hand, prevalence of HSV-2 antibodies was significantly higher among women. An extensive review of the prevalence of HSV-2 serum antibodies for different populations worldwide documents a higher prevalence among women [31]. Potential explanations for this finding include the higher efficiency of HSV-2 transmission from men to women as compared with that from women to men and differences between women and men in sexual behaviors [10, 31].

Prevalence of antibodies to viral hepatitis and HSV-2 was significantly higher in those with lower socioeconomic status in Puerto Rico, defined as having less than a high school education, living below the poverty level or having a public or no health insurance. Epidemiologic studies worldwide have shown an inverse association between HAV seropositivity and socioeconomic indicators, particularly in developing countries [13, 25]. Similarly, studies show socioeconomic status, poverty and geography to be major determinants of STIs disparities [5, 6].

In general, prevalence of viral infections was higher among higher risk sexual behavior groups. Although efficiency of sexual transmission of HCV appears to be relatively low, the dose-response relationships observed between prevalence of anti-HCV and age at first sexual relation and number of lifetime sexual partners is in agreement with other studies [2, 11, 17]. Recent surveillance data for acute viral hepatitis in the US during 2007 found that 42% of cases reported having multiple sex partners, 10% reported having sexual contact with another known HCV infected person, and 10% were men who had sex with men [2]. Prevalence of past or present HBV infection was higher for individuals who had their first sexual intercourse before the age of 12 years than among those whose first sex was later in life. HSV-2 seroprevalence for adults who reported having had at least two sexual partners was more than twice the seroprevalence for those who reported only one or no sexual partner in their lifetime. HIV seropositivity was significantly higher in men who ever reported sex with other men than in men who did not report same-sex contact. These observations are consistent with surveillance findings and previous seroepidemiologic surveys and support the notion that adoption of HIV and other STIs' risk reduction behaviors should be encouraged for the general population, especially those at high risk, including barrier precautions to reduce the risk for exposure to these viral agents [10, 12, 14, 28, 32].

There is ample evidence showing that injection drug use is the single most important risk factor for HCV infection. In this study, prevalence of anti-HCV was 76% among those who reported lifetime injection drug use. In addition, prevalence of HCV antibodies among those who reported lifetime non-injection drug use was three-fold higher than those who reported no drug use. Prevalence of anti-HCV among IDU was higher than the reported figure in the NHANES 1999-2002 (57.5%) and in the US surveillance system for acute viral hepatitis during 1998-2007 (average: 44%; range: 38%-54%) [2, 11, 17]. Injection drug use was also common among HBV and HAV seropositive individuals, findings consistent with surveillance data for acute viral hepatitis in the US during 2007 [2].

Several infectious diseases have been found to be associated with a history of cosmetic procedures, such as tattooing and body piercing [34, 35]. In our study, individuals with a history of tattooing and body piercing practices had a higher HCV seroprevalence than those without such practices. Similarly, adults who reported a history of imprisonment were also more likely to be seropositive to HCV, HBV, HIV and HSV-2. These findings support the implementation of a comprehensive approach to prevent these infections in the correctional setting [36]. Further investigation is also required to determine if these types of exposures contribute to the transmission of blood borne pathogens in the general population.

The Centers for Disease Control and Prevention have estimated that blood transfusions might have been the source of HCV infection for nearly 7% of cases [2]. In our study, 6.3% of adults who had a history of receiving blood transfusions prior to 1992 were three-fold more likely to be HCV seropositive than individuals without such a history. Similarly, individuals who reported receipt of blood transfusions also had a higher prevalence of antibodies for HBV and HIV, possibly reflecting the high risk of acquiring these infections via transfused blood products prior to the introduction of more sensitive screening techniques to improve blood supply safety or from units donated during the antibody-negative window period before seroconversion [37].

A higher seroprevalence of HIV and HSV-2 was observed among adults who self-reported a history of other STIs including syphilis, gonorrhea, genital warts, and chlamydia infection. These findings are in agreement with seroprevalence surveys and surveillance data in the US, that show that the two most commonly reported STIs in the US, chlamydia and gonorrhea, along with syphilis and herpes, have been associated with an increased transmission of HIV [3, 57]. Moreover, numerous observational studies suggest that genital herpes is associated with an increased risk of HIV acquisition and may account for 40% to 60% of new HIV infections in high HSV-2 prevalence populations [32, 38]. When concomitant antibodies to viral infections under study were examined, individuals who were HSV-2 seropositive had a significantly higher prevalence of antibodies to HCV, HBV, HAV and HIV. Similarly, HBV seropositive individuals had a higher prevalence of antibodies to HCV and HAV. These findings support the view that viral hepatitis and STIs share similar at-risk populations and social determinants [5, 7, 8]. Continued efforts to prevent new infections in high risk groups are essential, along with expansion of target HAV and HBV vaccination programs, screening strategies for viral hepatitis and STIs, and preventive activities to reduce the progression in people with chronic hepatitis.

Strengths of our study are the inclusion of a probabilistic sample of adults which enhances the generalizability of the findings in Puerto Rico, an adequate response rate (78%), and extensive data regarding risk factors. This study also demonstrated the feasibility of conducting a household survey that combined face-to-face interviews, ACASI, and biochemical measurements in a mobile examination unit in Puerto Rico, a methodology similar to that used in the NHANES program. However, there are several limitations to be considered when interpreting the results of this study. Although the distribution of age, education level, and family income of our sample was comparable to that of the adult population of Puerto Rico, according to the US Census 2000 [24], females were overrepresented. However, prevalence of the viral infections under study was not affected when the corresponding proportions of males and females in Puerto Rico from the Census 2000 were considered. Second, the small number of HIV positive individuals limited our ability to make reliable prevalence estimates according to sociodemographic and behavioral characteristics. Third, prevalence of anti-HCV and anti-HBV does not distinguish between recent or remote infection, so these estimates do not shed light on the current burden of chronic viral hepatitis. Finally, other well-known risk factors for HCV infection, such as long-term hemodialysis, history of organ transplantation, and health care work involving frequent exposure to blood, were not evaluated because of their low frequency. However, CDC estimates that these risk factors generally account for fewer than 10% of HCV infections [2].

Notwithstanding these limitations, this study represents a further step toward a true understanding of the burden of these viral infections in Puerto Rico. Prevention and control of these infections is challenging given their asymptomatic nature. Immunization strategies have been developed to eliminate the spread of HBV and HAV infections. However, there are currently no licensed vaccines to prevent the acquisition of HCV, HIV and HSV-2, thus, prevention of these infections mostly depends on preventing high-risk injecting and sexual behaviors.

Conclusions

This study sheds light on the epidemiology of viral hepatitis, HIV and HSV-2 infections and underscores their disproportionate impact among specific population subgroups in Puerto Rico. Further research and policy development are urgently needed to strengthen viral hepatitis and STIs prevention and control strategies, improve surveillance of these infections, and provide integrated health services to ensure appropriate counseling, testing, and medical management of infected persons.

Declarations

Acknowledgements

This study was fully supported by the NIGMS MBRS-SCORE Program (S06-GM08224) and partially supported by RCMI (G12RR03051), NCRR (P20RR011126) and NCI (U54CA96297) grants of the NIH. This project also received an unrestricted grant from Glaxo-Smithkline Inc. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the sponsors. Sponsors of this study had no part in the design, data collection, analysis or interpretation of the findings of this study, and did not take part in the writing or the decision to publish this manuscript.

Authors’ Affiliations

(1)
Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico
(2)
Center for Sociomedical Research and Evaluation, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico
(3)
Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, University of Puerto Rico
(4)
Puerto Rico Cancer Center, School of Medicine, Medical Sciences Campus, University of Puerto Rico
(5)
Department of Medicine, School of Medicine, Medical Sciences Campus, University of Puerto Rico

References

  1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD: Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009, 3: 353-367. 10.1586/egh.09.35.View ArticlePubMedGoogle Scholar
  2. Centers for Disease Control and Prevention: Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ. 2009, 58: 1-27.Google Scholar
  3. Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance, 2007. 2008, Atlanta, Georgia: U.S. Department of Health and Human ServicesGoogle Scholar
  4. Chesson HW, Collins D, Koski K: Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States. Cost Eff Resour Alloc. 2008, 6: 10-10.1186/1478-7547-6-10.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Centers for Disease Control and Prevention: Addressing social determinants of health: Accelerating the prevention and control of HIV/AIDS, viral hepatitis, STD and TB. External Consultation Meeting Report. 2009, Atlanta, Georgia: Centers for Disease Control and PreventionGoogle Scholar
  6. Newman LM, Berman SM: Epidemiology of STD disparities in African American communities. Sex Transm Dis. 2008, 35 (Suppl 12): S4-S12.View ArticlePubMedGoogle Scholar
  7. Wasserheit JN: Epidemiological synergy, interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992, 19: 61-77.View ArticlePubMedGoogle Scholar
  8. Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol. 2008, 48: 353-367. 10.1016/j.jhep.2007.11.009.View ArticlePubMedGoogle Scholar
  9. McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kington RS: Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health. 2004, 94: 1952-1958. 10.2105/AJPH.94.11.1952.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006, 296: 964-973. 10.1001/jama.296.8.964.View ArticlePubMedGoogle Scholar
  11. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006, 144: 705-714.View ArticlePubMedGoogle Scholar
  12. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999, 89: 14-18.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Bell BP, Kruszon-Moran D, Shapiro CN, Lambert SB, McQuillan GM, Margolis HS: Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine. 2005, 23: 5798-5806. 10.1016/j.vaccine.2005.03.060.View ArticlePubMedGoogle Scholar
  14. McQuillan GM, Kruszon-Moran D, Granade T, Feldman JW: Seroprevalence of human immunodeficiency virus in the US household population aged 18-49 years: the National Health and Nutrition Examination Surveys, 1999-2006. J Acquir Immune Defic Syndr. 2009.Google Scholar
  15. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2007. 2009, Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 1-63.Google Scholar
  16. Centers for Disease Control and Prevention: Incidence and Diagnoses of HIV Infection - Puerto Rico, 2006. MMWR. 2009, 58: 589-591.Google Scholar
  17. Pérez CM, Suárez E, Torres EA, Román K, Colón V: Seroprevalence of hepatitis C virus and associated risk behaviors: a population-based study in San Juan, Puerto Rico. Int J Epidemiol. 2005, 34: 593-599. 10.1093/ije/dyi059.View ArticlePubMedGoogle Scholar
  18. Pérez CM, Marrero E, Meléndez M, Adrovet S, Ortiz AP, Colón HM, Albizu C, Torres EA, Suárez E: Feasibility of collecting biologic specimens in population-based surveys: experiences from the Epidemiology of Hepatitis C in the Adult Population of Puerto Rico study. P R Health Sci J. 2010, 29: 18-25.PubMedPubMed CentralGoogle Scholar
  19. Colón H, Pérez CM, Meléndez M, Marrero E, Ortiz AP, Suárez E: The validity of drug use responses in a household survey in Puerto Rico: comparison of survey responses with urinalysis. Addict Behav. 2010.Google Scholar
  20. Puerto Rico Department of Health, Division of Epidemiology, AIDS Surveillance System. 2002
  21. Pan W: Sample size and power calculations with correlated binary data. Control Clin Trials. 2000, 22: 211-227. 10.1016/S0197-2456(01)00131-3.View ArticleGoogle Scholar
  22. Hardin JW, Hilbe JM: Generalized estimating equations. 2003, Boca Raton: Chapman & Hall/CRCGoogle Scholar
  23. U.S. Census Bureau: Puerto Rico Municipio Population Estimates by Age and Sex (Vintage 2008): April 1, 2000 to July 1, 2008. [http://www.census.gov/popest/municipios/prmasrh.html]
  24. US Census Bureau: Census 2000 Summary File 1, Puerto Rico. [http://www.census.gov/Press-Release/www/2001/sumfile1.html]
  25. Jacobsen KH, Koopman JS: Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004, 132: 1005-1022. 10.1017/S0950268804002857.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Raoult D, Foucault C, Brouqui P: Infections in the homeless. Lancet Infect Dis. 2001, 1: 77-84. 10.1016/S1473-3099(01)00062-7.View ArticlePubMedGoogle Scholar
  27. Flanigan TP, Zaller N, Taylor L, Beckwith C, Kuester L, Rich J, Carpenter CC: HIV and infectious disease care in jails and prisons: breaking down the walls with the help of academic medicine. Trans Am Clin Climatol Assoc. 2009, 120: 73-83.PubMedPubMed CentralGoogle Scholar
  28. Schillinger JA, McKinney CM, Garg R, Gwynn RC, White K, Lee F, Blank S, Thorpe L, Frieden T: Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis. 2008, 35: 599-606. 10.1097/OLQ.0b013e3181666fb1.View ArticlePubMedGoogle Scholar
  29. Centers for Disease Control and Prevention: HIV prevalence estimates - United States, 2006. MMWR Recomm Rep. 2008, 57: 1073-1076.Google Scholar
  30. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ: Applying public health principles to the HIV epidemic. N Engl J Med. 2005, 353: 2397-2402. 10.1056/NEJMsb053133.View ArticlePubMedGoogle Scholar
  31. Centers for Disease Control and Prevention: Use of social networks to identify persons with undiagnosed HIV infection - seven US Cities - October 2003-September 2004. MMWR. 2005, 54: 601-605.Google Scholar
  32. Smith JS, Robinson NJ: Age-specific prevalence of infection with herpes simplex types 2 and 1: a global review. J Infect Dis. 2002, 186 (Suppl 1): S3-S28. 10.1086/343739.View ArticlePubMedGoogle Scholar
  33. Reyes JC, Colón HM, Robles RR, Rios E, Matos TD, Negrón J, Marrero CA, Calderón JM, Shepard E: Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico. J Urban Health. 2006, 83: 1105-13. 10.1007/s11524-006-9109-7.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Haley RW, Fischer RP: The tattooing paradox: are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection?. Arch Intern Med. 2003, 163: 1095-1108. 10.1001/archinte.163.9.1095.View ArticlePubMedGoogle Scholar
  35. Abiona TC, Balogun JA, Adefuye AS, Sloan PE: Body art practices among inmates: implications for transmission of bloodborne infections. Am J Infect Control. 2010, 38: 121-129. 10.1016/j.ajic.2009.06.006.View ArticlePubMedGoogle Scholar
  36. Hammet TM: HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health. 2006, 96: 974-978. 10.2105/AJPH.2005.066993.View ArticleGoogle Scholar
  37. Gonzalez M, Règine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ: Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion. 2005, 45: 1670-1675. 10.1111/j.1537-2995.2005.00576.x.View ArticlePubMedGoogle Scholar
  38. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006, 20: 73-83. 10.1097/01.aids.0000198081.09337.a7.View ArticlePubMedGoogle Scholar
  39. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/10/76/prepub

Copyright

© Pérez et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement